McKesson (NYSE:MCK) Price Target Lowered to $1,015.00 at JPMorgan Chase & Co.

McKesson (NYSE:MCK) had its target price decreased by JPMorgan Chase & Co. from $1,107.00 to $1,015.00 in a report released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

MCK has been the topic of a number of other research reports. Mizuho raised their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. UBS Group raised their target price on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings restated a “buy (b+)” rating on shares of McKesson in a report on Monday. Robert W. Baird set a $968.00 target price on McKesson in a report on Wednesday, January 14th. Finally, Wall Street Zen upgraded McKesson from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus price target of $970.73.

McKesson Stock Performance

Shares of McKesson stock opened at $734.93 on Friday. McKesson has a 52 week low of $637.00 and a 52 week high of $999.00. The stock has a 50 day moving average price of $883.74 and a two-hundred day moving average price of $859.93. The stock has a market capitalization of $90.02 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 1.09 and a beta of 0.35.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 378.75% and a net margin of 1.18%.The firm had revenue of $96.30 billion during the quarter, compared to analysts’ expectations of $101.35 billion. During the same quarter last year, the firm posted $10.12 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Research analysts forecast that McKesson will post 44.24 EPS for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 8.53%.

Insider Buying and Selling

In related news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president owned 2,989 shares in the company, valued at $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,264 shares of company stock worth $3,205,315. 0.08% of the stock is owned by company insiders.

Institutional Trading of McKesson

A number of hedge funds have recently bought and sold shares of MCK. GGM Financials LLC bought a new stake in McKesson during the third quarter worth $25,000. University of Texas Texas AM Investment Management Co. bought a new stake in McKesson during the fourth quarter worth $25,000. Swiss RE Ltd. bought a new stake in McKesson during the fourth quarter worth $26,000. State of Wyoming bought a new stake in McKesson during the second quarter worth $29,000. Finally, Hopwood Financial Services Inc. bought a new stake in McKesson during the third quarter worth $31,000. 85.07% of the stock is currently owned by institutional investors.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat quarterly adjusted EPS estimates, reporting $11.69 per share versus $11.56 expected, and cited strength in oncology, specialty distribution, and biopharma services. Reuters article
• Positive Sentiment: The company guided fiscal 2027 EPS to $43.80-$44.60, which is roughly in line with expectations and suggests continued earnings growth. McKesson also reaffirmed its long-term financial targets. Yahoo Finance article
• Positive Sentiment: JPMorgan lowered its price target to $1,015 from $1,107 but kept an overweight rating, implying meaningful upside from the current share price. Benzinga article
• Positive Sentiment: William Blair reiterated a Buy rating, saying McKesson’s durable earnings power and fiscal 2027 growth outlook outweigh near-term revenue softness. TipRanks article
• Neutral Sentiment: McKesson advanced plans for its $13 billion medical-surgical spinoff/separation, a strategic move that could unlock value over time but also adds execution risk. MSN article
• Negative Sentiment: Revenue came in below Wall Street forecasts at $96.3 billion versus $101.35 billion expected, reinforcing concerns about softer sales momentum despite improved margins. Yahoo Finance article
• Negative Sentiment: The stock has been trading lower as investors focus on the revenue shortfall and near-term softness in the medical-surgical business, even with strong earnings and guidance. Zacks article

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.